Biond Biologics Ltd.

Biond Biologies Ltd.

Dror Alishekevitz

Avidor Shulman

Yair Sapir

Dana Haves Ziv

Motti Hakim

Tsuri Peretz

Ilana Goldshtein

Anna Fridman-Dror

Ilana Mandel

Tehila Ben-moshe

Tehila Ben-Moshe

Edna Meilin

The present invention provides monoclonal antibodies, or antigen-binding portions thereof, against ILT2, as well as pharmaceutical compositions comprising same and methods of producing same. Also provided are methods of treating cancer comprising administering the antibodies or compositions of the invention. Methods of treating cancer, combination treatments, and patient selection are also provided.

Methods of use for anti-ILT2 antibodies

Methods of treating cancer and improving immunotherapies comprising decreasing soluble immune receptor levels are provided. Agents that bind membranal immune receptor and inhibit proteolytic cleavage of the receptor and agents that bind soluble immune receptor and that are neither receptor agonists nor antagonists are also provided, as are methods of producing these agents.

Methods and compositions for decreasing soluble immune receptor CD28

The present disclosure provides monoclonal anti-ILT2 antibodies or antigen-binding fragments thereof, as well as pharmaceutical compositions comprising the same and methods of producing the same. Also provided are methods of treating cancer using the antibodies or compositions of the present disclosure. Methods of patient selection are also provided.

Antibodies against ILT2 and use thereof

Antibodies against ILT2

Growing community of inventors

Kiryat Tivon, Israel

Dror Alishekevitz